PDCD1LG2 and cancer: Despite obtaining a significant antitumor immune response after the application of CAR T cell therapy, ICI therapy (such as CTLA-4, PD-1, PD-L1, and PD-L2), NK-cell-based therapy, and the DC vaccine in a wide range of cancers, many individuals continue to have difficulty responding to cancer therapies.